Advertisement

Topics

Companies Related to "Apomorphine Injection Parkinson Disease" [Most Relevant Company Matches] - Page: 4 [Advanced Search Results] RSS

10:25 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Apomorphine Injection Parkinson Disease" found in our extensive corporate database of over 50,000 company records.

Showing "Apomorphine Injection Parkinson Disease" Companies 76–100 of 2,800+

Probably Relevant

Motac

Motac Neuroscience provides highly-specialised services for the pharmaceutical and biotechnology industries to support the discovery and development of therapeutics for neurological and psychiatric disorders. Motac personnel have extensive expertise in neurodegenerative conditions, particularly Parkinson's disease and other movement disorders.Motac also has an intellectual property portfolio prote...


XenoTech, LLC

XenoTech's reputation as a leader in drug metabolism research originated in 1983 with Dr. Andrew Parkinson's studies of cytochrome P450 (CYP) enzymes. Dr. Parkinson founded XenoTech in 1994 to provide products and contract research services to optimize the discovery, development and approval of drugs, food additives, nutraceuticals, agrochemicals, cosmetics and fragrances. XenoTech's products and ...

Novocell, Inc

Novocell’s goal is to develop a renewable source of specialized cells that can be used to treat chronic cellular diseases. To achieve this goal, Novocell is uniquely positioned to exploit human stem cell engineered product opportunities using its proprietary cell encapsulation technology. Combined with Novocell's expertise in cell transplantation, these technologies will allow large numbers of p...


Nova Molecular Incorporated

Nova Molecular Inc. (NMI) is a Montreal based CNS drug discovery company focused on understanding neuronal degeneration, disease progression, repair mechanisms, therapeutic response and development based on our proprietary neuron repair biology platform. NMI’s lead Alzheimer’s compound is also under investigation for a number of other CNS neurodegenerative indications such as Parkinson’s, mu...

Embrex Incorporated

Embrex, Inc. develops and markets biological delivery technology and biological products to increase the productivity andprofitability of the global poultry industry. Embrex has developed and commercialized the INOVOJECT(R) system, a proprietary, automated in-the-egg injection system which can inoculate 20,000 to 50,000 eggs per hour and eliminates the need for manual, post-hatch injection of cert...

Zygogen, LLC

Zygogen LLC is a privately owned, Atlanta-based biotechnology company founded in 1999 to develop proprietary zebrafish models of human disease for preclinical drug discovery. Zebrafish offer a powerful combination of low cost, high throughput analysis and complex vertebrate biology that can be observed in the living organism. A pioneer in applying zebrafish technology to drug discovery, Zygogen wa...

AGY Therapeutics Incorporated

AGY is an emerging biopharmaceutical company, discovering and developing novel treatments for diseases of the nervous system. AGY scientists have established and utilized a unique mechanism-based approach to identify and characterize new molecules for disease intervention. The intricate molecular networks activated by stress, injury, infection, degeneration and toxins offer a unique basis for sele...

Progenra Inc.

Progenra (www.progenra.com) aims to discover and develop novel medicines exploiting the ubiquitin proteasome system. Progenra has achieved leadership in ubiquitin proteasome system by utilizing the company’s UbiPro™ Drug Discovery Platform. Progenra has identified novel therapeutically relevant molecules for Parkinson’s disease by targeting ...

pharmacia Corporation

Pharmacia is a top-tier global pharmaceutical company, with a leading agricultural subsidiary. We have built a portfolio of outstanding products, led by our key growth drivers: CELEBREX® (celecoxib capsules), CAMPTOSAR® (irinotecan hydrochloride injection), XALATAN® (latanoprost ophthalmic solution), DETROL®LA (tolterodine tartrate extended release capsules), and ZYVOX™ (linezolid injection,...

Cavion, Inc.

Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies modulating the T-type calcium channel (Cav3) for the treatment of neurological diseases. Cavion’s platform of Cav3 modulators restore the brain’s natural rhythms in a variety of chronic neurological diseases such as essential tremor, Parkinson’s disease, neurop...

Parkinson's Unity Walk

PixarBio Corporation

PixarBio Corporation is dedicated to developing new therapeutic options for Parkinson’s disease. Co-founded by Robert S. Langer from MIT’s Langer Lab and Frank Reynolds, the company is developing novel smart materials to achieve sustained release of dopamine, or dopamine agonists. Research is focused on a platform for chronic neurological applica...

Elan

Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan's focus on improving the health of patients suffering from chronic and debilitating conditions is exemplified by its breakthrough research program in Alzheimer's disease, where it has...

Parkinson Foundation of Western Pennsylvania

Neuropore Therapies Inc.

Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. The approach being taken by Neuropore is to target an underlying pathological process common to these disorders – the accumulation of toxic oligomeric aggregates of ...

Neuropore Therapies, Inc.

Neuropore Therapies is developing novel small molecule therapeutics to treat and slow the progression of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. The approach being taken by Neuropore is to target an underlying pathological process common to these disorders – the accumulation of toxic oligomeric aggregates of ...

Lysosomal Therapeutics Inc.

Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a ...

Amarantus BioScience Holdings, Inc.

Amarantus is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to M...

Muhammad Ali Parkinson Center

The Michael Stern Parkinson's Research Foundation

Zenobia Therapeutics, Inc.

Zenobia provides a commercial fragment library and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there are no disease-altering t...

Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases. The Company owns the intellectual property rights ...

XenoPort, Inc.

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). The adu...

Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of neurotrophic (or nervous system growth) factors for the treatment of neurodegenerative and retinal disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's...


More From BioPortfolio on "Apomorphine Injection Parkinson Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks